Ajay Major, MD, MBA
@majorajay.bsky.social
Lymphoma/CLL faculty at the University of Colorado School of Medicine. Patient-reported outcomes methodologist & #lymsm quality of life investigator. #medsky
Get stoked for this year’s #MajorPROsASH!
I’m currently reviewing all the patient-reported outcomes (PRO) abstracts @ash.hematology.org to curate the top 20 PRO & quality of life abstracts from #ASH25.
Thread dropping next week! 🧵 #mmsm #leusm #lymsm
I’m currently reviewing all the patient-reported outcomes (PRO) abstracts @ash.hematology.org to curate the top 20 PRO & quality of life abstracts from #ASH25.
Thread dropping next week! 🧵 #mmsm #leusm #lymsm
November 25, 2025 at 8:49 PM
Get stoked for this year’s #MajorPROsASH!
I’m currently reviewing all the patient-reported outcomes (PRO) abstracts @ash.hematology.org to curate the top 20 PRO & quality of life abstracts from #ASH25.
Thread dropping next week! 🧵 #mmsm #leusm #lymsm
I’m currently reviewing all the patient-reported outcomes (PRO) abstracts @ash.hematology.org to curate the top 20 PRO & quality of life abstracts from #ASH25.
Thread dropping next week! 🧵 #mmsm #leusm #lymsm
Double-dose axi-cel 2L high-risk LBCL #ASH25
- 15 pts, 69% refractory, 4 couldn't get 2nd dose
- no DLTs w/i 28 days
- ORR 91% (CR 73%), 6-mo PFS 79%, 100% OS
- 3 G1 CRS/ICANS after 2nd dose
Correlative data: less CAR exhaustion & better cytotox after 2nd dose. #lymsm #tcellrx
- 15 pts, 69% refractory, 4 couldn't get 2nd dose
- no DLTs w/i 28 days
- ORR 91% (CR 73%), 6-mo PFS 79%, 100% OS
- 3 G1 CRS/ICANS after 2nd dose
Correlative data: less CAR exhaustion & better cytotox after 2nd dose. #lymsm #tcellrx
November 24, 2025 at 6:32 PM
Pirto vs BR 1L CLL LBA #ASH25
- 282 pts (TP53mut not allowed)
- 2-yr PFS 93% with pirto, 71% with BR
- superior OS with pirto despite 53% crossover
- PFS benefit seen in IGHV unmut
- G5 AEs: 1 pirto, 4 BR; more d/c with BR
Not a useful comparator arm, but very few pirto AEs. #lymsm
- 282 pts (TP53mut not allowed)
- 2-yr PFS 93% with pirto, 71% with BR
- superior OS with pirto despite 53% crossover
- PFS benefit seen in IGHV unmut
- G5 AEs: 1 pirto, 4 BR; more d/c with BR
Not a useful comparator arm, but very few pirto AEs. #lymsm
November 24, 2025 at 5:40 PM
The #ASH25 late-breaking abstracts are out! Will review the pirto vs BR abstract shortly. #lymsm cc @ash.hematology.org submit.hematology.org/program/sess...
November 24, 2025 at 5:35 PM
The #ASH25 late-breaking abstracts are out! Will review the pirto vs BR abstract shortly. #lymsm cc @ash.hematology.org submit.hematology.org/program/sess...
Excited to work with this phenomenal team of hematologists on ASH News Daily for #ASH25 this year!
Be sure to check out our first set of articles here: ashpublications.org/ashnewsdaily...
#ASHNewsDaily @ash.hematology.org
Be sure to check out our first set of articles here: ashpublications.org/ashnewsdaily...
#ASHNewsDaily @ash.hematology.org
November 18, 2025 at 8:04 PM
Excited to work with this phenomenal team of hematologists on ASH News Daily for #ASH25 this year!
Be sure to check out our first set of articles here: ashpublications.org/ashnewsdaily...
#ASHNewsDaily @ash.hematology.org
Be sure to check out our first set of articles here: ashpublications.org/ashnewsdaily...
#ASHNewsDaily @ash.hematology.org
Neuropathy in ASPEN trial (ibr v zanu in WM)
- 49/201 w/ baseline PN (clinician assessed; no PN PRO included); 10 anti-MAG
- 71% PN resolution (median 10 mos)
- much better global QOL improvement if PN resolved
Need PRO PN studies in WM. #lymsm #ASH25
www.sciencedirect.com/science/arti...
- 49/201 w/ baseline PN (clinician assessed; no PN PRO included); 10 anti-MAG
- 71% PN resolution (median 10 mos)
- much better global QOL improvement if PN resolved
Need PRO PN studies in WM. #lymsm #ASH25
www.sciencedirect.com/science/arti...
November 17, 2025 at 9:15 PM
Neuropathy in ASPEN trial (ibr v zanu in WM)
- 49/201 w/ baseline PN (clinician assessed; no PN PRO included); 10 anti-MAG
- 71% PN resolution (median 10 mos)
- much better global QOL improvement if PN resolved
Need PRO PN studies in WM. #lymsm #ASH25
www.sciencedirect.com/science/arti...
- 49/201 w/ baseline PN (clinician assessed; no PN PRO included); 10 anti-MAG
- 71% PN resolution (median 10 mos)
- much better global QOL improvement if PN resolved
Need PRO PN studies in WM. #lymsm #ASH25
www.sciencedirect.com/science/arti...
RW outcomes CD19 CAR Burkitt
- 31 pts, 3 prior LOT, most axi-cel
- 65% G3+ CRS, 19% G3+ ICANS
- 16% D+28 mortality (!!!)
- 6-mo CR 19%, mPFS 2.3 mos, mOS 6 mos
- 3 pts who got post-CAR allo all relapsed
Dismal outcomes & unmet need (BsAb? alloCAR?) #lymsm #ASH25 ashpublications.org/blood/articl...
- 31 pts, 3 prior LOT, most axi-cel
- 65% G3+ CRS, 19% G3+ ICANS
- 16% D+28 mortality (!!!)
- 6-mo CR 19%, mPFS 2.3 mos, mOS 6 mos
- 3 pts who got post-CAR allo all relapsed
Dismal outcomes & unmet need (BsAb? alloCAR?) #lymsm #ASH25 ashpublications.org/blood/articl...
November 17, 2025 at 8:21 PM
RW outcomes CD19 CAR Burkitt
- 31 pts, 3 prior LOT, most axi-cel
- 65% G3+ CRS, 19% G3+ ICANS
- 16% D+28 mortality (!!!)
- 6-mo CR 19%, mPFS 2.3 mos, mOS 6 mos
- 3 pts who got post-CAR allo all relapsed
Dismal outcomes & unmet need (BsAb? alloCAR?) #lymsm #ASH25 ashpublications.org/blood/articl...
- 31 pts, 3 prior LOT, most axi-cel
- 65% G3+ CRS, 19% G3+ ICANS
- 16% D+28 mortality (!!!)
- 6-mo CR 19%, mPFS 2.3 mos, mOS 6 mos
- 3 pts who got post-CAR allo all relapsed
Dismal outcomes & unmet need (BsAb? alloCAR?) #lymsm #ASH25 ashpublications.org/blood/articl...
I'm writing for #ASHNewsDaily this year! Check out my article previewing #ASH25 Education Program talks about immunotherapies invading earlier lines of therapy, including interviews with Drs. Doris Hansen, Nicolas Boissel & Sarah Rutherford. cc @ash.hematology.org
ashpublications.org/ashnewsdaily...
ashpublications.org/ashnewsdaily...
November 17, 2025 at 4:28 PM
I'm writing for #ASHNewsDaily this year! Check out my article previewing #ASH25 Education Program talks about immunotherapies invading earlier lines of therapy, including interviews with Drs. Doris Hansen, Nicolas Boissel & Sarah Rutherford. cc @ash.hematology.org
ashpublications.org/ashnewsdaily...
ashpublications.org/ashnewsdaily...
This is what happens when all the junior @cuhematology.bsky.social lymphoma faculty have clinic on Fridays. #lymsm 😂😂
November 14, 2025 at 6:59 PM
This is what happens when all the junior @cuhematology.bsky.social lymphoma faculty have clinic on Fridays. #lymsm 😂😂
Announcing the MAGIC-ONC guidelines for the placement and management of vascular access devices in patients with cancer, including specific recommendations for both hematologic and solid tumor malignancies. #MAGICOnc #oncsky #medsky
www.acpjournals.org/doi/epdf/10.... cc @cuanschutz.bsky.social
www.acpjournals.org/doi/epdf/10.... cc @cuanschutz.bsky.social
November 4, 2025 at 10:47 PM
Announcing the MAGIC-ONC guidelines for the placement and management of vascular access devices in patients with cancer, including specific recommendations for both hematologic and solid tumor malignancies. #MAGICOnc #oncsky #medsky
www.acpjournals.org/doi/epdf/10.... cc @cuanschutz.bsky.social
www.acpjournals.org/doi/epdf/10.... cc @cuanschutz.bsky.social
Late night publication (finally!) of our MAGIC-ONC appropriateness guidelines for vascular access in patients with cancer, now in @annalsofim.bsky.social. More to come tomorrow! #medsky #oncsky www.acpjournals.org/doi/full/10....
November 4, 2025 at 2:16 AM
Late night publication (finally!) of our MAGIC-ONC appropriateness guidelines for vascular access in patients with cancer, now in @annalsofim.bsky.social. More to come tomorrow! #medsky #oncsky www.acpjournals.org/doi/full/10....
Dr. Valerie Crabtree @stjude.bsky.social presented the findings of our qualitative study of patient and care partner perspectives in NLPHL at @worldsiop.bsky.social #SIOPCongress. Read our study here: pubmed.ncbi.nlm.nih.gov/40059593/ #lymsm cc @cucancercenter.bsky.social @cuanschutz.bsky.social
October 30, 2025 at 8:26 PM
Dr. Valerie Crabtree @stjude.bsky.social presented the findings of our qualitative study of patient and care partner perspectives in NLPHL at @worldsiop.bsky.social #SIOPCongress. Read our study here: pubmed.ncbi.nlm.nih.gov/40059593/ #lymsm cc @cucancercenter.bsky.social @cuanschutz.bsky.social
This morning's meeting of our monthly @accordsresearch.bsky.social imPROve Patient-Reported Outcomes Working Group. Phenomenal group of @cuanschutz.bsky.social @cucancercenter.bsky.social investigators working on new quality of life studies. #HRQoL medschool.cuanschutz.edu/accords/rese...
October 28, 2025 at 3:40 PM
This morning's meeting of our monthly @accordsresearch.bsky.social imPROve Patient-Reported Outcomes Working Group. Phenomenal group of @cuanschutz.bsky.social @cucancercenter.bsky.social investigators working on new quality of life studies. #HRQoL medschool.cuanschutz.edu/accords/rese...
RW pola outcomes by Hans COO @eddiecliff.bsky.social
- 740 pts, 59% R/R
- R/R: ORR 60% non-GC (vs 36% GC), PFS better in non-GC
- 1L: no diff in outcomes
Hans useful in choosing pola in R/R. In 1L, supports POLARIX that pola mitigates worse non-GC outcomes. #lymsm
aacrjournals.org/clincancerre...
- 740 pts, 59% R/R
- R/R: ORR 60% non-GC (vs 36% GC), PFS better in non-GC
- 1L: no diff in outcomes
Hans useful in choosing pola in R/R. In 1L, supports POLARIX that pola mitigates worse non-GC outcomes. #lymsm
aacrjournals.org/clincancerre...
October 27, 2025 at 4:30 PM
RW pola outcomes by Hans COO @eddiecliff.bsky.social
- 740 pts, 59% R/R
- R/R: ORR 60% non-GC (vs 36% GC), PFS better in non-GC
- 1L: no diff in outcomes
Hans useful in choosing pola in R/R. In 1L, supports POLARIX that pola mitigates worse non-GC outcomes. #lymsm
aacrjournals.org/clincancerre...
- 740 pts, 59% R/R
- R/R: ORR 60% non-GC (vs 36% GC), PFS better in non-GC
- 1L: no diff in outcomes
Hans useful in choosing pola in R/R. In 1L, supports POLARIX that pola mitigates worse non-GC outcomes. #lymsm
aacrjournals.org/clincancerre...
The first report of quality of life in patients with NLPHL from our ongoing NLPHLPRO multicenter trial (NCT06098430), presented by Dr. Jones at #ISCAYAHL.
Long-term survivors (most who received chemo) have low symptom burden and high global QOL & functioning. #lymsm cc @cuhematology.bsky.social
Long-term survivors (most who received chemo) have low symptom burden and high global QOL & functioning. #lymsm cc @cuhematology.bsky.social
October 23, 2025 at 8:05 PM
The first report of quality of life in patients with NLPHL from our ongoing NLPHLPRO multicenter trial (NCT06098430), presented by Dr. Jones at #ISCAYAHL.
Long-term survivors (most who received chemo) have low symptom burden and high global QOL & functioning. #lymsm cc @cuhematology.bsky.social
Long-term survivors (most who received chemo) have low symptom burden and high global QOL & functioning. #lymsm cc @cuhematology.bsky.social
Interested in adding PROs to your study, or developing a quality of life project?
Come to our imPROve Working Group @accordsresearch.bsky.social to get feedback from PRO researchers across @childrenscolo.bsky.social @cuanschutz.bsky.social. #oncsky
medschool.cuanschutz.edu/accords/rese...
Come to our imPROve Working Group @accordsresearch.bsky.social to get feedback from PRO researchers across @childrenscolo.bsky.social @cuanschutz.bsky.social. #oncsky
medschool.cuanschutz.edu/accords/rese...
October 20, 2025 at 5:06 PM
Interested in adding PROs to your study, or developing a quality of life project?
Come to our imPROve Working Group @accordsresearch.bsky.social to get feedback from PRO researchers across @childrenscolo.bsky.social @cuanschutz.bsky.social. #oncsky
medschool.cuanschutz.edu/accords/rese...
Come to our imPROve Working Group @accordsresearch.bsky.social to get feedback from PRO researchers across @childrenscolo.bsky.social @cuanschutz.bsky.social. #oncsky
medschool.cuanschutz.edu/accords/rese...
Patient- vs clinician-reported AEs from POLARIX @bloodjournals.hematology.org:
- symptom incidence & severity much higher measured by PROs
- sustained improvements in all QOL domains except cog functioning (worse R-CHOP arm)
We must measure PROs in #lymsm trials!
ashpublications.org/blood/articl...
- symptom incidence & severity much higher measured by PROs
- sustained improvements in all QOL domains except cog functioning (worse R-CHOP arm)
We must measure PROs in #lymsm trials!
ashpublications.org/blood/articl...
October 14, 2025 at 7:58 PM
Patient- vs clinician-reported AEs from POLARIX @bloodjournals.hematology.org:
- symptom incidence & severity much higher measured by PROs
- sustained improvements in all QOL domains except cog functioning (worse R-CHOP arm)
We must measure PROs in #lymsm trials!
ashpublications.org/blood/articl...
- symptom incidence & severity much higher measured by PROs
- sustained improvements in all QOL domains except cog functioning (worse R-CHOP arm)
We must measure PROs in #lymsm trials!
ashpublications.org/blood/articl...
CNS penetration of pola @bloodadvances.bsky.social
- 3 pts (1 PCNSL, 2 SCNSL): 2 had CR (although these pts received IT chemo & ibrutinib, respectively)
- pola detected in CSF of CNSL & systemic LBCL pts
Provocative but unclear about single-agent activity. #lymsm
ashpublications.org/bloodadvance...
- 3 pts (1 PCNSL, 2 SCNSL): 2 had CR (although these pts received IT chemo & ibrutinib, respectively)
- pola detected in CSF of CNSL & systemic LBCL pts
Provocative but unclear about single-agent activity. #lymsm
ashpublications.org/bloodadvance...
October 9, 2025 at 9:46 PM
CNS penetration of pola @bloodadvances.bsky.social
- 3 pts (1 PCNSL, 2 SCNSL): 2 had CR (although these pts received IT chemo & ibrutinib, respectively)
- pola detected in CSF of CNSL & systemic LBCL pts
Provocative but unclear about single-agent activity. #lymsm
ashpublications.org/bloodadvance...
- 3 pts (1 PCNSL, 2 SCNSL): 2 had CR (although these pts received IT chemo & ibrutinib, respectively)
- pola detected in CSF of CNSL & systemic LBCL pts
Provocative but unclear about single-agent activity. #lymsm
ashpublications.org/bloodadvance...
Childhood cancer survivors face higher mortality after colorectal secondary cancers, with 50% diagnosed before age 40. Our new JNCI manuscript highlights need for tailored screening guidelines. #medsky #oncsky #survonc academic.oup.com/jnci/advance...
August 24, 2025 at 5:43 PM
Childhood cancer survivors face higher mortality after colorectal secondary cancers, with 50% diagnosed before age 40. Our new JNCI manuscript highlights need for tailored screening guidelines. #medsky #oncsky #survonc academic.oup.com/jnci/advance...
Survival after incidental vs symptomatic FL:
- 908 pts, 29% incidental
- incidental: more early stage & normal LDH
- no diff in EFS, lymphoma-specific survival, or OS between groups
We can answer the "what if this was picked up earlier" question! #lymsm
www.nature.com/articles/s41...
- 908 pts, 29% incidental
- incidental: more early stage & normal LDH
- no diff in EFS, lymphoma-specific survival, or OS between groups
We can answer the "what if this was picked up earlier" question! #lymsm
www.nature.com/articles/s41...
August 17, 2025 at 8:45 PM
Survival after incidental vs symptomatic FL:
- 908 pts, 29% incidental
- incidental: more early stage & normal LDH
- no diff in EFS, lymphoma-specific survival, or OS between groups
We can answer the "what if this was picked up earlier" question! #lymsm
www.nature.com/articles/s41...
- 908 pts, 29% incidental
- incidental: more early stage & normal LDH
- no diff in EFS, lymphoma-specific survival, or OS between groups
We can answer the "what if this was picked up earlier" question! #lymsm
www.nature.com/articles/s41...
Is this my brand now, ASH?! Very honored to receive this award! 🤣😂 #ASHCRTI @ash.hematology.org
August 8, 2025 at 10:06 PM
Is this my brand now, ASH?! Very honored to receive this award! 🤣😂 #ASHCRTI @ash.hematology.org
Our CRTI group PROs and Poop! 💩 (intersection of patient-reported outcomes and fecal microbiome) #ASHCRTI cc @ash.hematology.org @biostatgirl.bsky.social
August 5, 2025 at 10:45 PM
Our CRTI group PROs and Poop! 💩 (intersection of patient-reported outcomes and fecal microbiome) #ASHCRTI cc @ash.hematology.org @biostatgirl.bsky.social
Day 1 of @ash.hematology.org CRTI! Super excited to learn from all these phenomenal investigators and faculty this week. #medsky #ASHKudos
August 3, 2025 at 3:08 PM
Day 1 of @ash.hematology.org CRTI! Super excited to learn from all these phenomenal investigators and faculty this week. #medsky #ASHKudos